Observed Signal · Oct 23, 2026 · Clinical Data Presentation · Source: PR Newswire: Advertising & Marketing · Impact: 1/5 · Sentiment: Positive

Intensity Therapeutics Presents INVINCIBLE-4 TNBC Data

Executive Signal Summary

Intensity Therapeutics announced that data from the first seven patients in Cohort A of the INVINCIBLE-4 study will be presented at the ESMO 2026 congress. The study evaluates INT230-6, an intratumoral therapy, in combination with neoadjuvant immunochemotherapy (NAIC) for early-stage triple-negative breast cancer (TNBC). Results showed a pathological complete response (pCR) in the breast and lymph nodes in 5 of 7 patients (71%). No invasive cancer cells in axillary lymph nodes were detected in 6 of 7 patients, despite 71% being initially node-positive. Tumor necrosis was observed in all patients after 1-2 injections. Adverse events were low grade, with dose-limiting skin reactions. The data suggest potential efficacy of INT230-6 in this setting.

Polaris7 AgentPolaris7 Strategic Assessment
High Confidence

Clinical data from a biotech company is relevant to the healthcare sector but not directly to AdTech, MarTech, or digital advertising.

MARKET SIGNALS

Track Biotech Signals & Market Shifts

Polaris7 connects regulatory filings, primary sources, leadership changes, and M&A activity into structured intelligence. Set up your Polaris7 workspace to monitor relevant companies in your executive briefing.

  • Verified primary sources
  • Automated briefings
  • Instant watchlist setup

Key Takeaways & Evidence Grounding

  • INT230-6 plus standard-of-care achieved pCR in breast and lymph nodes in 5 of 7 patients (71% CI 29-96%) in Cohort A.
  • No invasive breast cancer cells in axillary lymph nodes in 6 of 7 patients after INT230-6 treatment.
  • Tumor necrosis observed in all 7 patients after 1-2 injections.
  • Results to be presented at ESMO 2026 Virtual Congress starting October 23, 2026.
  • Dose-limiting local skin reactions occurred; one injection at lower volume now used due to protocol amendment.
Primary Source Grounding & Direct Attribution
Direct Origin Attribution
Primary Reporting: PR Newswire: Advertising & Marketing•Published: Oct 23, 2026
Original Coverage Title: “Intensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in an ePoster Presentation at the European Society of Medical Oncology (ESMO) Meeting”

Related Market Signals & Shifts

Recent verified developments and strategic activity across this market segment.

Product & Platform LaunchSep 3, 2026

AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma

Etentamig, an investigational asset, achieved a significantly improved objective response rate (ORR, 74%) and a 60% risk reduction in disease progression or death (progression-free survival,...

Read assessment
Health care / BiotechSep 24, 2026

REGENXBIO Presents Positive 3-Year Data for Sura-vec in Diabetic Retinopathy

REGENXBIO Inc. announced positive three-year durability data from the Phase II ALTITUDE study of its investigational gene therapy surabgene lomparvovec (sura-vec, ABBV-RGX-314) for diabetic retinopathy (DR), presented at the Retina Society 59th Annual Scientific Meeting. The data showed that a majority of Dose Level 3 participants with non-proliferative DR (NPDR) achieved a >2-step improvement on the Diabetic Retinopathy Severity Scale (DRSS) at three years after a single, in-office suprachoroidal injection, with no vision-threatening events and no additional treatment for DR. No intraocular inflammation (IOI) was observed with short-course prophylactic topical steroids. These results support the potential of sura-vec as a one-time treatment that could reduce the burden of repeat injections for patients.

Read assessment
BiotechNov 16, 2026

Fortvita Biologics Gets First Positive CHMP Opinion for Zybrivo

Fortvita Biologics, a member of the Innovent Group, announced its first positive opinion from the European Medicines Agency's CHMP. The opinion recommends marketing authorization for Zybrivo (sintilimab) in combination with chemotherapy for the first-line treatment of adults with advanced non-squamous non-small cell lung cancer. If approved by the European Commission, Zybrivo would be available across all 27 EU member states plus Iceland, Norway, and Liechtenstein. The recommendation is based on the Phase 3 ORIENT-11 study, which showed a 52% reduction in the hazard of disease progression or death and a 35% reduction in the hazard of death versus placebo plus chemotherapy. Fortvita is strengthening its capabilities for European market access. This is the first medicine in Fortvita's globalization strategy beyond China.

Read assessment

WATCHLIST & BRIEFINGS

Receive future signals for Biotech in your Watchlist briefing

Stay ahead of material M&A deals, leadership changes, account wins, and product rollouts. Polaris7 connects primary filings, company newsrooms, and trade reporting directly into your executive briefing.

  • Regular primary-source checks
  • Structured Watchlist briefings
  • Preserves current context